CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 42 enrolled
Drug / intervention
dexmedetomidine group +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01474213
NCT01474213Phase 4Completed

Dexmedetomidine Versus Remifentanil Target Controlled Infusion for Sedation During Awake Fibreoptic Nasotracheal Intubation

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·interventional·Posted Nov 18, 2011·Updated Nov 21, 2012

In Brief

A Phase 4 clinical trial evaluating dexmedetomidine group and remifentanil group for Intubation; Difficult. Completed, enrolled 42 participants across 2 sites.

Detailed Summary

The purpose of this study is to compare the sedation effect of dexmedetomidine and target controlled remifentanil for awake nasotracheal fibreoptic intubation in patients undergoing oral maxillofacial surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2011
Enrollment StartNov 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.6 years ago

Interventions

dexmedetomidine groupdrug

1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine

remifentanil groupdrug

target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)